Medroxyprogesterone

Chemical name

(6альфа)-17-(Гидрокси)-6-м етилпрегн-4-ен-3,20-дион (and in the form of acetate)

Gross

C22-H32-O3

Characteristics

White or no white crystalline powder and odourless, sustained in the air. Rat in acetone and dioxane, partly in ethanol and methanol, it is difficult, on the airwaves, nerastvorim in water.

Of drugs

The drugs-progestagennoe, containing, protivoopujolevoe. Ingibiruet secretion gonadotropinov gipofizom prevents follicle maturation and ovulation, helps istoncent endometrium. In high doses in the normal estrogen content of the transformation proliferativogo endometrium in secretornyi. Perhaps a androgennogo and anaboliceski Effectov.svazavanie with plasma protein-90-95%, T_1/2-30 p.m. Metabolised in the liver. Report mostly in the urine of Metabolita.pri admission to contraception reduces the risk of inflammatory diseases of the genital organs, kandidoznogo vulvowaginita. Given the high contraceptive effectiveness and the impact of the гормонально-зависимы�� bodies of the women late reproductive and older preferable, especially when there giperplasticeskih the endometrium, mioma uterus, endometriosis. Most women with hyperplastic processes endometrium is the partial or complete regression. When breast cancer is the correlation between the effectiveness of treatment and the concentration of estrogen receptors and progesterone in neoplastic tissue.

Indications

Contraception, especially among women delaying childbearing age; Amino, and retidivirute metastaticalkie cell endometrium and kidney (more palliative therapy), гормонально-зависимы�� retidivirutego forms of breast cancer among women Postmenopause.vnutri is secondary amenorea, dysfunctional uterine bleeding, pre syndrome, vazomotorne symptoms of menopause, endometriosis, diagnosis of primary and secondary amenorrhea, prevention and treatment of osteoporosis in postmenopauzne period (in combination with estrogenami drugs and calcium) preventing endometrium changes in the substitution therapy estrogenami in postmenopause.

Contraindications

Hypersensitivity, throm, tromboamboliceski syndrome or stroke in disorder, liver disease, bleeding from the vagina unspecified etiology, pregnancy, breast-feeding (no).

Side-Effects

Violations menstrual cycle tromboembolia, insomnia, irritability, drowsiness, a sense of fatigue, weakness, depression, dizziness, headaches, swelling, nausea, pain and discomfort in the abdomen, pain mammary glands, galactorea, erosion of the cervix, girsutizm, alopecia, fever, change in body mass index, lunoobraznoe person osteoporosis, urticaria, skin, acne, anaphylaxis and anaphylactoidnye reaction.

Specific guidance

Against the backdrop of the admission medroksiprogesteron may change the results of a number of laboratory tests (including сульфабромофталеинов ого and other functional liver tests), the reduction of steroids in the plasma and urine (progesterone, estradiol, pregnandiol, testosterone, kortizol) gonadotropinov, globulina linking sex hormones, the T_3, increasing protrombina factors VII, VIII, IX and X.

Patient interaction

Aminoglutetimid reduces plasma concentration and reduces efficiency.

Precautions

The reception should be appointed only on the 5th day of normal menstruation (guarantee of pregnancy). There is a need to use an alternate method of contraception during the two weeks after the first injection. Every three months to injection (more reliable contraceptives). If a change cycle at the time of admission to a doctor consultation. In dysfunctional uterine artistic methods to exclude cervical cancer and other organic destruction. Tape development trombofiliceskih states (throm, cerebrovascular violations tromboembolia branches of pulmonary artery thrombosis kidney) requires immediate repeal. There is a need for caution in epilepsy, migraine, asthma, cardiac and renal failure and the possible delay liquid. Be wary appoint diabetes, the depressed conditions.

Dosing and Administration

V / m, as a contraceptive and for the lifting of vazomotornah symptoms of menopause-150 mg every 3 months; Endometriose to 50 mg once a week or 100 mg every two weeks course at least 6 Mes.v / in, in the endometrium cancer or kidney-400-1000 mg weekly, in the pursuit of clinical improvement is 400 mg once a Mexiaz.vnutri in endometrium cancer or kidney-200-600 mg / day, with breast cancer, 400-1,200 mg / sut. For the prevention and treatment of osteoporosis in postmenopause, with 15 to 25 day of the month following the 5-10 mg once a day.

Directory → Antineoplastic funds → Antineoplastic hormonal and hormone antagonists → Medroxyprogesterone